Browse News

Found 8 articles

• AFYX Therapeutics Appoints Dennis Kim, M.D., MBA, as Chief Medical Officer

  11/18/2020

  AFYX Therapeutics ("AFYX"), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the appointment of Dennis D. Kim, M.D., MBA, as chief medical officer.

• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

• AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

  4/22/2020

    AFYX Therapeutics  ("AFYX"), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin ® Clobetasol patch ("Rivelin-CLO") met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus ("OLP"). In t

• Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs

  11/26/2019

  Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, announced that its advisory unit, BiOrigin, has appointed several seasoned entrepreneurs to its team.

• AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress

  10/9/2019

  AFYX Therapeutics announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus, a painful genital skin condition that affects up to 3% of post-menopausal women.

• AFYX Therapeutics Closes $13 Million Convertible Loan Financing

  6/24/2019

  Funds support the completion of ongoing Phase 2b study in Oral Lichen Planus

• AFYX Therapeutics Presents Framework for Patient-Reported Oral Lichen Planus Symptom Severity Measure at the 2019 American Academy of Oral Medicine Annual Conference

  5/23/2019

  AFYX Therapeutics announced findings from the development of a novel Oral Lichen Planus Symptom Severity Measure as a tool used to assess patients' symptom experience on a daily basis.

• AFYX Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of the Rivelin Patch in Patients with Vulvar Lichen Sclerosus

  12/4/2018

  AFYX Therapeutics today announced that it has completed enrollment in its Phase 1 clinical trial of the Rivelin patch in patients with vulvar lichen sclerosus (VLS).